Diplomat Pharmacy to dispense KISQALI as breast cancer tretament

Diplomat Pharmacy Inc. will dispense KISQALI as a first-line treatment for postmenopausal women with serious forms of breast cancer.
The company, via a press release, noted that the U.S. Food and Drug Administration approved KISQALI for use as a daily oral therapy to be used in conjunction with an aromatase inhibitor. The drug is approved to help women who are past menopause deal with advanced or metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor receptor 2–negative.
“The diagnosis of advanced or metastatic breast cancer has a devastating impact on patients, as well as their loved ones,” Diplomat President Paul Urick said in a statement. “KISQALI is a groundbreaking new treatment that can improve quality of life for our patients.”
Diplomat also noted the American Cancer Society reports breast cancer is the second-most common cancer among American women. More than 315,000 women are expected to be diagnosed with the disease in 2017.